New approaches to defining value and innovation in healthcare
The European Healthcare Innovation Leadership Network focused on advancing European healthcare innovation to address unmet needs and ensure patient access to valuable treatments in an era of severe budgetary pressures.
The network served as the catalyst for six multistakeholder drug development pilots which enabled regulators, health technology assessors, payers, patients, and medical experts from the EU and several of its member states to jointly advise pharmaceutical companies on development decisions regarding early-stage medicines, ranging from Phase 1 to Phase 3 products. These pilots paved the way to design and eventually institutionalize the parallel scientific advice process in Europe whereby payers and regulators jointly assess the efficacy, safety, and clinical utility of drugs as they advance in the development process.
The network also designed specific working groups to develop disease-specific value frameworks in diabetes and breast cancer. Finally, it addressed many other critical topics pertaining to improving patient outcomes, market access, and health systems improvement and readiness, including an initiative to examine multistakeholder platforms for accelerating the innovation and delivery of Alzheimer’s treatments.
Project Background:
From 2006 through 2012, the network brought together leaders of multiple European healthcare institutions. Members included public- and private-sector leaders who represented regulators, health technology assessors, healthcare budget holders, patient representatives, civil society, and medicine developers. AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, and Johnson & Johnson supported this network, along with Roche and GE. Tapestry’s work helping to develop and institutionalize the parallel scientific advice process in Europe has been acknowledged in academic journals as well as by government and leading private healthcare institutions.
Tapestry’s work helping to develop and institutionalize the parallel scientific advice process in Europe has been acknowledged in academic journals as well as by government and leading private healthcare institutions.
